dronabinol has been researched along with Disease Exacerbation in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chande, N; Kafil, TS; MacDonald, JK; Nguyen, TM | 2 |
| Chan, H; Desapriya, E; Peng, YW; R Brubacher, J | 1 |
| Arroyo González, R | 1 |
| Arterberry, BJ; Foster, KT; Hicks, BM; Treloar Padovano, H; Zucker, RA | 1 |
| Ball, S; Cano, MG; Hobart, J; Mallik, S; McManus, D; Miller, D; Nunn, A; Vickery, J; Wright, D; Zajicek, J | 1 |
| Cousijn, J; de Haan, L; Goudriaan, AE; Koenders, L; van den Brink, W; Vingerhoets, WA; Wiers, RW | 1 |
| Amedee, AM; Birke, LL; Lacour, N; LeCapitaine, NJ; Molina, PE; Nichols, WA; Stouwe, CV; Winsauer, PJ | 1 |
| Ball, S; Cano, MG; Green, C; Hobart, J; MacManus, D; Mallik, S; Miller, D; Nunn, A; Shearer, J; Vickery, J; Wright, D; Zajicek, J | 1 |
| Carrillo-Salinas, FJ; de Lago, E; Feliú, A; Fernández-Ruiz, J; Guaza, C; Mecha, M; Moreno-Martet, M | 1 |
| Hill, M | 1 |
| Bartalesi, B; De Cunto, G; Fineschi, S; Galeazzi, M; Garcia Gonzalez, E; Lorenzini, S; Lucattelli, M; Lungarella, G; Selvi, E | 1 |
| Fernández-Ruiz, J; Pazos, MR; Pertwee, RG; Ramos, JA; Sagredo, O; Satta, V | 1 |
| Arnaud, C; Burger, F; Frossard, JL; Karsak, M; Mach, F; Pelli, G; Staub, C; Steffens, S; Veillard, NR; Zimmer, A | 1 |
| Hong, S; Kliot, M; Möller, T; Stella, N; Weydt, P; Witting, A | 1 |
| Blázquez, C; Duarte, MJ; Galve-Roperh, I; González-Feria, L; Guzmán, M; Ravina, J; Rosa, MC; Sánchez, C; Velasco, G | 1 |
| Caffarel, MM; Cerutti, C; Guzman, M; Mechta-Grigoriou, F; Moreno-Bueno, G; Palacios, J; Sanchez, C | 1 |
| Dubinett, SM; Roth, MD; Tashkin, DP | 1 |
5 review(s) available for dronabinol and Disease Exacerbation
| Article | Year |
|---|---|
Cannabis for the Treatment of Crohn's Disease and Ulcerative Colitis: Evidence From Cochrane Reviews.
Topics: Adult; Cannabidiol; Colitis, Ulcerative; Crohn Disease; Disease Progression; Dronabinol; Humans; Marijuana Smoking; Medical Marijuana; Phytotherapy; Quality of Life; Randomized Controlled Trials as Topic; Remission Induction | 2020 |
"Residual blood THC levels in frequent cannabis users after over four hours of abstinence: A systematic review."
Topics: Accidents, Traffic; Adult; Cannabis; Disease Progression; Dronabinol; Female; Hallucinogens; Humans; Male; Marijuana Smoking; Substance-Related Disorders | 2020 |
A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Topics: Baclofen; Cannabidiol; Disease Progression; Dronabinol; Drug Combinations; Gait Disorders, Neurologic; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Nasal Sprays; Plant Extracts; Quality of Life | 2018 |
Cannabis for the treatment of Crohn's disease.
Topics: Adult; Cannabidiol; Crohn Disease; Disease Progression; Dronabinol; Humans; Marijuana Smoking; Medical Marijuana; Phytotherapy; Quality of Life; Randomized Controlled Trials as Topic; Remission Induction | 2018 |
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Topics: Adult; Cannabinoid Receptor Agonists; Disease Progression; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Treatment Outcome | 2013 |
3 trial(s) available for dronabinol and Disease Exacerbation
| Article | Year |
|---|---|
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Topics: Adult; Cannabinoid Receptor Agonists; Disease Progression; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Treatment Outcome | 2013 |
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Topics: Administration, Oral; Adult; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Dronabinol; Female; Financing, Government; Financing, Personal; Humans; Kaplan-Meier Estimate; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Muscle Spasticity; Neuroimaging; Outcome Assessment, Health Care; Proportional Hazards Models; Quality-Adjusted Life Years; Severity of Illness Index; Time Factors; United Kingdom | 2015 |
A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Brain Neoplasms; Cannabinoid Receptor Antagonists; Cell Proliferation; Disease Progression; Dronabinol; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Receptors, Cannabinoid; Safety; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2006 |
11 other study(ies) available for dronabinol and Disease Exacerbation
| Article | Year |
|---|---|
Higher average potency across the United States is associated with progression to first cannabis use disorder symptom.
Topics: Adolescent; Adult; Cannabis; Child; Disease Progression; Dronabinol; Female; Hallucinogens; Humans; Longitudinal Studies; Male; Marijuana Abuse; Marijuana Smoking; Michigan; Prospective Studies; United States; Young Adult | 2019 |
Relationship between working-memory network function and substance use: a 3-year longitudinal fMRI study in heavy cannabis users and controls.
Topics: Adolescent; Adult; Age of Onset; Analysis of Variance; Behavior, Addictive; Brain; Brain Mapping; Case-Control Studies; Disease Progression; Dronabinol; Female; Humans; Image Interpretation, Computer-Assisted; Linear Models; Longitudinal Studies; Magnetic Resonance Imaging; Male; Marijuana Abuse; Memory Disorders; Memory, Short-Term; Nerve Net; Neuropsychological Tests; Psychotropic Drugs; Risk Factors; Severity of Illness Index; Substance-Related Disorders; Young Adult | 2014 |
Chronic Δ⁹-tetrahydrocannabinol administration may not attenuate simian immunodeficiency virus disease progression in female rhesus macaques.
Topics: Animals; CD4-CD8 Ratio; Disease Progression; Dronabinol; Female; Macaca mulatta; Menstrual Cycle; Receptors, CXCR4; Simian Acquired Immunodeficiency Syndrome; Viral Load; Weight Loss | 2014 |
A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
Topics: Animals; Cannabidiol; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Drug Therapy, Combination; Mice; Mice, Inbred Strains; Multiple Sclerosis; Plant Extracts; Theilovirus | 2015 |
Perspective: Be clear about the real risks.
Topics: Cannabis; Disease Progression; Dronabinol; Humans; Mental Health; Pharmacogenetics; Risk; Schizophrenia | 2015 |
Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung.
Topics: Actins; Administration, Inhalation; Animals; Anti-Inflammatory Agents; Bleomycin; Collagen; Connective Tissue Growth Factor; Cytoprotection; Disease Models, Animal; Disease Progression; Dronabinol; Drug Administration Schedule; Hydroxyproline; Lung; Male; Mice, Inbred DBA; Phosphorylation; PPAR gamma; Pulmonary Fibrosis; Signal Transduction; Smad2 Protein; Smad3 Protein; Time Factors; Transforming Growth Factor beta1 | 2016 |
Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.
Topics: Animals; Cannabidiol; Cannabinoids; Caudate Nucleus; Cells, Cultured; Disease Models, Animal; Disease Progression; Dronabinol; Drug Combinations; Huntington Disease; Male; Neostriatum; Neuroprotective Agents; Phytotherapy; Plant Extracts; Putamen; Rats; Rats, Sprague-Dawley | 2011 |
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Cells, Cultured; Chemotaxis, Leukocyte; Disease Models, Animal; Disease Progression; Dronabinol; Humans; Inflammation; Interferon-gamma; Macrophages; Mice; Mice, Knockout; Receptor, Cannabinoid, CB2; Receptors, CCR2; Receptors, Chemokine; RNA, Messenger; Survival Rate; Th1 Cells; Thioglycolates; Tumor Necrosis Factor-alpha | 2005 |
Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival.
Topics: Age Factors; Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Disease Progression; Dronabinol; Male; Mice; Mice, Transgenic; Probability; Psychotropic Drugs; Superoxide Dismutase; Survival | 2005 |
JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Nucleus; Cell Proliferation; Cell Survival; Disease Progression; Dronabinol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-jun; Tumor Cells, Cultured; Up-Regulation | 2008 |
Medicinal marijuana?
Topics: AIDS-Related Opportunistic Infections; Cannabis; Disease Progression; Dronabinol; HIV Infections; Humans; Marijuana Smoking | 1997 |